GSK CEO on earnings, Shingrix sales and consumer business split

Subscribe to The Global Herald in Google News

CNBC Television published this video item, entitled “GSK CEO on earnings, Shingrix sales and consumer business split” – below is their description.

GlaxoSmithKline CEO Emma Walmsley joins ‘Squawk on the Street’ to discuss the company’s latest earnings report and its planned consumer business split.

CNBC Television YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.


Subscribe to The Global Herald in Google News

About This Source - CNBC Television

CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.

As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.

Recent from CNBC Television:

  • U.S.A.F. Sec. Kendall: We’re in a race for technological superiority with China
  • There was an overreaction to Chinese tech regulation news, says Krane Funds CIO
  • Millennial tested and Cramer approved: CNBC launches new Next Generation 50 index
  • In This Story: GlaxoSmithKline

    GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.

    Established in 2000, by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co.

    GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.

    The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.

    The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization‘s List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.

    In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company.

    2 Recent Items: GlaxoSmithKline

  • ‘Ground-breaking’ malaria vaccine approved for African children
  • WHO Endorses World’s First-Ever Malaria Vaccine After Decades of Work
  • Leave a Comment

    We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.

    Posting....